Association between corticosteroid therapy during acute COVID-19 and Long COVID symptoms: a propensity score overlap-weighted analysis - 12/08/26
, Hideki Terai a, c, Hiromu Tanaka a, Shuhei Azekawa a, Shin Iizuka a, Takuya Ozawa a, Genta Nagao a, Kensuke Nakagawara a, Atsuho Morita a, Akinari Atsumi a, Kazuma Yagi b, Masanori Kaji a, Akihiko Ogata a, Shunichiro Konishi a, Emiko Matsuyama a, Fumimaro Ito a, Hatsuyo Takaoka a, Lisa Shigematsu a, Takashi Shimada a, Shiro Otake a, Keeya Sunata a, Masahiko Okada a, Takahiro Fukushima a, Keiko Ohgino a, Katsunori Masaki a, Jun Miyata a, Japan COVID-19 Task Force
Naoki Hasegawa b, Shotaro Chubachi a, Ho Namkoong b, Koichi Fukunaga a
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Abstract |
Background |
The association between acute-phase corticosteroid therapy and subsequent Long COVID symptoms remains uncertain. Therefore, we aimed to evaluate the association between systemic corticosteroid therapy during hospitalization and patient-reported Long COVID symptoms during follow-up.
Methods |
In this prospective multicenter observational study, we enrolled adults hospitalized with laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection at 26 hospitals in Japan between January 2020 and February 2021. To account for evolving corticosteroid prescription practices, we used propensity score overlap weighting with calendar time adjustment relative to the RECOVERY trial announcement and fit overlap-weighted mixed-effects logistic regression models to estimate longitudinal associations across follow-up (3, 6, and 12 months). Additionally, symptom-specific outcomes were evaluated at 3 months.
Results |
Among the 1044 participants, 373 received systemic corticosteroids and 671 did not. Corticosteroid therapy was associated with higher odds of any Long COVID symptom during follow-up (OR: 1.71; 95% CI: 1.12–2.63). In exploratory subgroup analyses stratified by oxygen requirement, no clear association was observed among patients who required oxygen therapy during hospitalization, whereas the association was more apparent among those who did not require oxygen therapy. At 3 months, corticosteroid therapy was associated with muscle weakness (OR: 2.43; 95% CI: 1.27–4.65).
Conclusions |
In this observational overlap-weighted analysis, acute-phase systemic corticosteroid therapy during COVID-19 hospitalization was associated with higher odds of patient-reported Long COVID symptoms during follow-up. However, these findings should not be interpreted as evidence against appropriately indicated corticosteroid therapy in patients with hypoxemic COVID-19 or respiratory failure.
Le texte complet de cet article est disponible en PDF.Highlights |
• | Long-term effects of acute-phase corticosteroids remain uncertain. |
• | Overlap weighting was applied in a multicenter COVID-19 cohort. |
• | Corticosteroid exposure was linked to higher odds of Long COVID symptoms. |
• | No clear association was seen among patients requiring oxygen therapy. |
• | Neuromuscular symptoms showed prominent associations at 3 months. |
Keywords : Post-acute COVID-19 syndrome, SARS-CoV-2, Glucocorticoids, Patient-reported outcome measures, Cohort studies
Plan
Vol 261
Article 108914- septembre 2026 Retour au numéro
Article précédent
- Differential expression of succinylation in lung mitochondria of patients with chronic obstructive pulmonary disease and its correlation with oxidative stress
- Ting Meng, Xuelian Zhang, Yongjiang Bao, Mailipa Maihemuti, Changmin Jiang, Buayisha Alabaidi, Liyan Zhai
- Relationship between changes in intestinal desulfovibrio levels and oxygen desaturation in patients with obstructive sleep apnea syndrome
- Baran Sınır, Pinar Ortan, Sevgi Sidika Sayin, Ataç Uzel
Bienvenue sur EM-consulte, la référence des professionnels de santé.